AbbVie (FRA:4AB) Inventories, Raw Materials & Components: €957 Mil (As of Mar. 2026)


FRA:4AB AbbVie Inc FRA:4AB
82 GF Score
Price €218.00
GF Value €181.91
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is AbbVie Inventories, Raw Materials & Components?

AbbVie FRA:4AB +2.11% 82 Inventories, Raw Materials & Components is €957 Mil as of Mar. 2026. GuruFocus rates FRA:4AB with a GF Score™ of 82/100 and a GF Value™ of €181.91 (Modestly Overvalued). The stock has 4 warning signs investors should review.

AbbVie's inventories, raw materials & components for the quarter that ended in Mar. 2026 was €957 Mil.

AbbVie's quarterly raw materials increased from Sep. 2025 (€922 Mil) to Dec. 2025 (€926 Mil) and increased from Dec. 2025 (€926 Mil) to Mar. 2026 (€957 Mil).

AbbVie's annual raw materials increased from Dec. 2023 (€1,009 Mil) to Dec. 2024 (€1,009 Mil) but then declined from Dec. 2024 (€1,009 Mil) to Dec. 2025 (€926 Mil).

AbbVie Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for AbbVie's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie Inventories, Raw Materials & Components Chart

AbbVie Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 887.66 944.00 1,008.70 1,009.44 925.74

AbbVie Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,027.68 1,010.92 921.86 925.74 956.69
FRA:4AB
82GF Score
AbbVie Inc FRA:4AB
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbbVie Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of €957 Mil mean?
AbbVie (FRA:4AB) has a Inventories, Raw Materials & Components of €957 Mil as of Mar. 2026. Raw materials are the components a company uses for its main products. View historical data on AbbVie and its competitors.
Is AbbVie's Inventories, Raw Materials & Components too high?
AbbVie's current Inventories, Raw Materials & Components is €957 Mil. Overall, AbbVie has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's Inventories, Raw Materials & Components compare to MRK and JNJ?
AbbVie's Inventories, Raw Materials & Components of €957 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Drug Manufacturers company?
A good Inventories, Raw Materials & Components depends on the Drug Manufacturers industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on AbbVie and its competitors. AbbVie's current Inventories, Raw Materials & Components is €957 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (FRA:4AB) is currently considered Modestly Overvalued. The stock's GF Value™ is €181.91, compared to a current price of €218.00 — trading 19.8% above its estimated fair value. The current Inventories, Raw Materials & Components is €957 Mil. AbbVie's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For AbbVie (FRA:4AB), the current Inventories, Raw Materials & Components is €957 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbbVie (FRA:4AB) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of €218.00 is trading 19.8% above its estimated GF Value™ of €181.91. GuruFocus considers AbbVie to be Modestly Overvalued.

Key valuation signals for FRA:4AB:

  • Inventories, Raw Materials & Components: €957 Mil
  • GF Value™: €181.91 vs. price of €218.00 (19.8% above fair value)
  • GF Score™: 82/100 with 4 warning signs

No single metric tells the full story. See the FRA:4AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
82GF Score

Get the complete analysis for FRA:4AB

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€218.00
Price
€181.91
GF Value